Salvage high-dose-rate interventional radiotherapy (brachytherapy) for locally relapsed prostate cancer after radical prostatectomy and subsequent external irradiation.
biochemical failure
high-dose-rate brachytherapy
interventional radiotherapy
prostate cancer
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
02
12
2022
accepted:
23
05
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
ppublish
Résumé
To report the use of high-dose-rate (HDR) interventional radiotherapy (brachytherapy, IRT) as a salvage treatment for macroscopic histologically confirmed local relapse of prostatic cancer after prostatectomy and subsequent external irradiation. A retrospective study of patients with prostate adenocarcinoma, treated with HDR-IRT for an isolated local relapse after prostatectomy and external irradiation at our institution (2010-2020). Treatment results and treatment related-toxicity were recorded. Clinical outcomes were analyzed. Ten patients were identified. The median age was 63 years (range, 59-74 years), and the median follow-up time was 34 months (range, 10-68 months). Four patients had a biochemical relapse, and the mean time to prostate specific antigen (PSA) increase was 13 months. One-year biochemical failure-free survival (bFFS), 3-year bFFS, and 4-year bFFS were 80%, 60%, and 60%, respectively. Most of the treatment-related toxicities were grade 1-2. Two patients experienced grade 3 late genitourinary toxicity. HDR-IRT seems to be an effective treatment option showing acceptable toxicity for prostate cancer patients with isolated macroscopic histologically confirmed local relapse after prostatectomy and subsequent external irradiation.
Identifiants
pubmed: 37425206
doi: 10.5114/jcb.2023.128845
pii: 50890
pmc: PMC10324589
doi:
Types de publication
Journal Article
Langues
eng
Pagination
159-165Informations de copyright
Copyright © 2023 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
J Urol. 2009 Mar;181(3):956-62
pubmed: 19167731
Brachytherapy. 2021 Jan-Feb;20(1):19-28
pubmed: 32798180
Urology. 2003 Dec;62(6):1068-72
pubmed: 14665357
J Urol. 2009 Aug;182(2):517-25; discussion 525-7
pubmed: 19524984
Can J Urol. 2014 Jun;21(3):7283-9
pubmed: 24978358
Int Urol Nephrol. 2022 May;54(5):1031-1037
pubmed: 35239137
Brachytherapy. 2014 Mar-Apr;13(2):111-6
pubmed: 24373762
Lancet Oncol. 2020 Oct;21(10):1341-1352
pubmed: 33002438
Front Oncol. 2019 Feb 15;9:71
pubmed: 30828565
BJU Int. 2010 Jun;105(12):1642-5
pubmed: 19922544
J Contemp Brachytherapy. 2015 Aug;7(4):241-6
pubmed: 26622225
BJU Int. 2012 Feb;109 Suppl 1:17-21
pubmed: 22239225
Urology. 2011 Jun;77(6):1416-9
pubmed: 21492918
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
Brachytherapy. 2013 Jul-Aug;12(4):338-42
pubmed: 22748289
Brachytherapy. 2005;4(2):141-5
pubmed: 15893268
Lancet. 2012 Dec 8;380(9858):2018-27
pubmed: 23084481
Radiother Oncol. 2012 Nov;105(2):198-202
pubmed: 23068708
Brachytherapy. 2014 Mar-Apr;13(2):123-7
pubmed: 24269146
Eur Urol. 2021 Sep;80(3):306-315
pubmed: 34140144
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
World J Urol. 2009 Oct;27(5):607-12
pubmed: 19455340
Lancet. 2020 Oct 31;396(10260):1422-1431
pubmed: 33002431
BJR Open. 2019 Jun 07;1(1):20180027
pubmed: 33178921
Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):335-343
pubmed: 30312717
BJU Int. 2007 Oct;100(4):760-4
pubmed: 17662081
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):324-9
pubmed: 23474112
Eur Urol. 2015 May;67(5):825-36
pubmed: 25097095
Br J Radiol. 2019 Feb;92(1094):20180494
pubmed: 30379566
Cancers (Basel). 2022 Jan 29;14(3):
pubmed: 35158961
J Contemp Brachytherapy. 2016 Dec;8(6):477-483
pubmed: 28115952
Eur J Nucl Med Mol Imaging. 2017 May;44(5):776-787
pubmed: 27988802
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):378-84
pubmed: 22717242
Eur Urol. 2014 Aug;66(2):243-50
pubmed: 24680359
Cancers (Basel). 2022 Jul 26;14(15):
pubmed: 35892897